会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明申请
    • SKIN REGENERATION USING MESENCHYMAL STEM CELLS
    • 使用中胚层干细胞进行皮肤再生
    • WO1997041208A1
    • 1997-11-06
    • PCT/US1997006760
    • 1997-04-24
    • CASE WESTERN RESERVE UNIVERSITYSORRELL, J., MichaelCAPLAN, Arnold, I.
    • CASE WESTERN RESERVE UNIVERSITY
    • C12N05/00
    • A61L27/3891A61K35/12A61L27/3804A61L27/3813A61L27/3834A61L27/3886A61L27/3895A61L27/60C12N5/0656C12N5/0698C12N2502/094C12N2502/1323C12N2502/1358C12N2533/54
    • Disclosed is a multilayer skin equivalent having (i) a scaffold layer incorporated with dermis-forming cells, and (ii) a keratinocyte layer. Also disclosed is a multilayer dermal equivalent having at least one of (i) a first layer of at least one skin-associated extracellular matrix component containing papillary dermal fibroblasts; and, in laminar relationship therewith, (ii) a second layer of at least one skin-associated extracellular matrix component containing reticular dermal fibroblasts. Preferred embodiments include those where the scaffold or dermis-forming layer is a multilayer selected from the group consisting of (a) a layer containing isolated papillary dermis-forming cells and a layer containing isolated reticular dermis-forming cells; (b) a layer containing isolated papillary dermis-forming cells and a layer containing isolated, culture expanded mesenchymal stem cells; and (c) a layer containing isolated reticular dermis-forming cells and a layer containing isolated, culture expanded mesenchymal stem cells. Also enclosed is a multilayer skin equivalent having (i) a scaffold layer comprising a first layer of at least one skin-associated extracellular matrix component containing papillary dermal fibroblasts and, in laminar relationship therewith, a second layer of at least one skin-associated extracellular matrix component containing reticular dermal fibroblasts; and (ii) a keratinocyte layer. Also disclosed is an injectable composition of dermis-forming cells and at least one skin-associated extracellular matrix component in a pharmaceutically acceptable injectable carrier. The injectable composition can further include keratinocytes.
    • 公开了一种多层皮肤当量,其具有(i)与真皮形成细胞结合的支架层,和(ii)角质形成细胞层。 还公开了具有以下至少一种的多层皮肤当量:(i)含有乳头状真皮成纤维细胞的至少一种皮肤相关细胞外基质组分的第一层; 并且与其层状关系,(ii)含有网状真皮成纤维细胞的至少一种皮肤相关的细胞外基质组分的第二层。 优选的实施方案包括其中支架或真皮形成层是选自(a)含有分离的乳头状真皮细胞形成细胞层和含有分离的网状真皮形成细胞的层的多层的那些实例; (b)含有分离的乳头状真皮细胞的层和含有分离培养的扩展的间充质干细胞的层; 和(c)含有分离的网状真皮细胞的层和含有分离的培养扩展的间充质干细胞的层。 还包括多层皮肤等效物,其具有(i)支架层,其包含含有乳头状真皮成纤维细胞的至少一种皮肤相关细胞外基质组分的第一层,并且与其层叠,具有至少一种皮肤相关细胞外的第二层 含有网状真皮成纤维细胞的基质成分; 和(ii)角质形成细胞层。 还公开了在药学上可接受的可注射载体中的真皮形成细胞和至少一种与皮肤相关的细胞外基质组分的可注射组合物。 可注射组合物还可包含角质形成细胞。